NCT04728113 (EARLY TOGETHER) is a NA clinical trial of Supportive care visit with questionnaires in Uveal Melanoma, sponsored by Institut Curie.

Who is sponsoring NCT04728113?

NCT04728113 is sponsored by Institut Curie.

What drugs are being tested in NCT04728113?

Interventions in NCT04728113: Supportive care visit with questionnaires, Oncological standard visit.

What condition does NCT04728113 study?

NCT04728113 studies Uveal Melanoma.

Is NCT04728113 still recruiting?

NCT04728113 is currently completed. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT04728113: EARLY TOGETHER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)

Completed NA Last updated 8 September 2025

What this trial tests

NA trial testing Supportive care visit with questionnaires in Uveal Melanoma in 162 participants. Completed in 22 January 2025.

Timeline

16 July 2020

Primary endpoint
22 January 2025

22 January 2025

Quick facts

Lead sponsor	Institut Curie
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	162
Start date	16 July 2020
Primary completion	22 January 2025
Estimated completion	22 January 2025
Sites	2 locations across France

Drugs / interventions tested

Supportive care visit with questionnaires
Oncological standard visit

Conditions studied

Uveal Melanoma — all drugs for Uveal Melanoma →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, any sex, with Uveal Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study main objective is to assess whether the early introduction of supportive care demonstrates a benefit on patients' psychological care needs at 6 months (M6), versus oncological standard of care in patients with metastatic UM. Supportive care in patients with metastatic Uveal Melanoma (UM)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial.
Piperno-Neumann S, Koning L, Marchal T, Gastaud L, et al · · 2024 · PMID 39869447 · DOI 10.1080/20450885.2024.2382080

Verify or expand the search:

Other recruiting trials for Uveal Melanoma

Currently open trials in the same condition.

NCT07421739 — Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects · recruiting
NCT06070012 — Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06932757 — Adjuvant Quisinostat in High-Risk Uveal Melanoma · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
NCT06519266 — PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases · Phase 3 · recruiting

Other Institut Curie trials

Trials by the same sponsor.

NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04728113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Curie
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04728113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing